Cell Tech
Latest round
- Angel
Last raised
- Sep 2015
Total raised
- $1.6M
Investors
- 4
About Cell Tech
Based in Tianjin, China, and established in 2015, Cell Tech is a biotechnology company that focuses on research in the field of cell therapy.D.S. pharmaceutical companies. Cell Tech's main business is the research and development of cancer immune cell therapy. It uses genetically modified, patient's immune T-cells to fight and treat cancer. Its products can be categorized into 2 series, which are CAR-T classic products and hematological oncology CAR molecules. Products can be used for the treatment of acute lymphoblastic leukemia, non-Hodgkin's lymphoma, B-cell malignant tumors, and other diseases.
Who invested in Cell Tech
4 investors across 1 round
See all investors in Cell Tech
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Angel
Sep 29, 2015
Amount
$1.6M
Investors
Questions about Cell Tech
Who invested in Cell Tech?
Cell Tech has 4 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Cell Tech raised?
Cell Tech has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did Cell Tech last raise money?
Cell Tech's most recent round on record is a Angel, in Sep 2015.
What does Cell Tech do?
Based in Tianjin, China, and established in 2015, Cell Tech is a biotechnology company that focuses on research in the field of cell therapy.
Where is Cell Tech headquartered?
Cell Tech is headquartered in Tianjin, China.
Which VCs invest in companies like Cell Tech?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Peak XV Partners, MPCi and Luminous Ventures back biotechnology companies at Cell Tech's stage. Their profiles are linked below.
VCs backing biotechnology startups at Angel
Raising like Cell Tech? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.